Micro cap biotech trading well below cash value: Stockhouse Ticker Trax

World class potential in developing new pharmaceutical products his week's discussion topic I. Tiny biotech with world class potential trading well below cash value Thallion Pharmaceuticals (TSX: T.TLN, Stock Forum; 12 cents) www.thallion.com Shares outstanding: 32 million/ Market cap: $3.8 million Cash & investments Aug 31: $9 million (28 cents/share) Debt: $1.8 million ($ - 0.06/share) Thallion is an unknown, thinly-traded biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology, with a current emphasis on the development and commercialization of Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli (“STEC”) bacterial infections).

.